Ka Lung Wu
YOU?
Author Swipe
View article: B01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL)
B01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL) Open
Background. The phase III IsKia trial evaluated isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) as pre-ASCT induction and post-ASCT consolidation vs KRd in NDMM patients (pts). Here we report the rates of 1-year sustained (sust)…
View article: Bibliometrics and scientometrics analysis of exosomes relevance in hepatocellular carcinoma (2014-2024)
Bibliometrics and scientometrics analysis of exosomes relevance in hepatocellular carcinoma (2014-2024) Open
Background Exosomes have emerged as pivotal players in the pathogenesis, progression, and treatment of hepatocellular carcinoma (HCC), establishing them as a major research focus in recent years. This bibliometric analysis maps the knowled…
View article: 214 | FINAL INDEPENDENT REVIEW DATA SUPPORTS SUSTAINED BENEFIT OF ZANUBRUTINIB OVER IBRUTINIB IN PATIENTS WITH R/R CLL/SLL IN ALPINE
214 | FINAL INDEPENDENT REVIEW DATA SUPPORTS SUSTAINED BENEFIT OF ZANUBRUTINIB OVER IBRUTINIB IN PATIENTS WITH R/R CLL/SLL IN ALPINE Open
View article: Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT Open
Summary Allogeneic haematopoietic cell transplantation (allo‐HCT) remains an option for tyrosine kinase inhibitor‐resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high‐risk patients with advanced disease phases. I…
View article: R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial Open
View article: Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study Open
View article: S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Open
Background: Linvoseltamab is a BCMA×CD3 bispecific antibody with encouraging efficacy and a manageable safety profile in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (Bumma et al. ASH 2022). Aims: Two Phase (Ph) 2 full d…
View article: P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Autologous stem cell transplantation (ASCT) is known for its excellent outcomes in a selected group of AL amyloidosis patients but few data exist on long term outc…
View article: R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIAL
R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIAL Open
Background: Optimal first-line treatment for patients with high-risk Burkitt lymphoma (BL) remains to be defined. Treatment with high-dose multi-agent regimens such as R-CODOX-M/R-IVAC is effective at the cost of significant toxicity. In s…
View article: P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY Open
Introduction: Non-transplant eligible newly diagnosed multiple myeloma (NTE-NDMM) patients have a heterogeneous clinical outcome, depending of frailty level. The aim of this study was to prospectively investigate the efficacy and tolerabil…
View article: B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS Open
Introduction: Primary plasma cell leukemia (pPCL) is a rare, aggressive plasma cell disorder with poor prognosis. Median PFS for transplant-eligible pts is approx. 9 months. The EMN12/HOVON129 study assessed carfilzomib and lenalidomide in…
View article: B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS Open
Introduction: Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell disorder with poor prognosis. The EMN12/ HOVON-129 study assessed carfilzomib and lenalidomide as first-line therapy in pPCL. Pts ≥18 years were enrolle…
View article: R-CODOX-M/R-IVA Versus DA-EPOCH-R in Patients with Newly Diagnosed Burkitt Lymphoma. Final Results of A Multicenter Randomized HOVON/SAKK Trial
R-CODOX-M/R-IVA Versus DA-EPOCH-R in Patients with Newly Diagnosed Burkitt Lymphoma. Final Results of A Multicenter Randomized HOVON/SAKK Trial Open
View article: S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Open
Background: Despite recent advances in treatment options, multiple myeloma (MM) remains incurable. REGN5458 is a BCMAxCD3 bispecific antibody currently under investigation in relapsed/refractory MM (RRMM) in an ongoing Phase 1/2 trial (NCT…
View article: Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study Open
View article: Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study Open
View article: Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma
Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma Open
View article: Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Open
View article: Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma Open
View article: Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study Open
View article: Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial Open
This prospective, multicenter, phase II study investigated the use of four cycles of bortezomib-dexamethasone induction treatment, followed by high-dose melphalan and autologous stem cell transplantation (SCT) in patients with newly diagno…
View article: Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial Open
View article: Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors
Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors Open
Background: Anti-PD-L1 mAbs have demonstrated anti-tumor activities in multiple indications. CS1001 is the first full-length, fully human anti-PD-L1 mAb developed by OMT transgenic animal platform, which mirrors natural IgG4 human antibody…
View article: Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia Open
CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients…
View article: Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Open
Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Mye…